Apc 001
Alternative Names: Apc-001Latest Information Update: 05 Feb 2025
At a glance
- Originator Aptacure Therapeutics
- Class Oligonucleotides
- Mechanism of Action SOST protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical X-linked dominant hypophosphataemic rickets
Most Recent Events
- 23 Dec 2024 Preclinical trials in X-linked dominant hypophosphataemic rickets in Hongkong (unspecified route) prior to December 2024
- 23 Dec 2024 Apc 001 receives Orphan Drug status for X-linked dominant hypophosphataemic rickets in USA
- 23 Dec 2024 Apc 001 receives Rare pediatric disease designation for X-linked dominant hypophosphataemic rickets in USA